Study to Nivolumab Following Preoperative Chemoradiotherapy
A Phase 1b/2 Multicenter Study to Investigate the Safety, Efficacy and Proof of Concept (POC) of Nivolumab Monotherapy as a Sequential Therapy Following Preoperative Chemoradiotherapy Patients With Locally Advanced Resectable Rectal Cancer
Sponsor: Ono Pharmaceutical Co. Ltd
Listed as NCT02948348, this PHASE1/PHASE2 trial focuses on Cancer of Rectum and remains ongoing. Sponsored by Ono Pharmaceutical Co. Ltd, it has been updated 9 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Oct 2021 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Unknown Status → Recruiting
-
Jan 2021 — Oct 2021 [monthly]
Unknown Status PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jul 2020 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Jul 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ono Pharmaceutical Co. Ltd
- Takayuki Yoshino
For direct contact, visit the study record on ClinicalTrials.gov .